INVO Bioscience, Inc. and Medesole announced the signing of a joint venture to operate dedicated INVOcell clinics in India. INVOcell, also known as IVC, is the world's only in vivo Intravaginal Culture System, offering patients diagnosed with infertility an effective solution through a simplified, more natural and less costly process than traditional in-vitro fertilization (IVF). The new joint venture (JV) will operate under the nameMedesole INVO Bioscience Private Limited. Under terms of the agreement, INVO Bioscience and Medesole will each own 50% of the joint venture. INVO Bioscience will provide the device, training and general technology support to the joint venture, while Medesole will be responsible for the operations of the INVOcell clinics in India. Both partners will equally invest in start-up and capital expenditures and share in the revenue and profits of the joint venture. The joint venture, Medesole INVO Bioscience Private Limited, has set an initial objective of opening three INVOcell clinics over the next 12 months, with additional clinics planned in subsequent years. Based on the initial first year plan, INVO Bioscience anticipates it will invest approximately $150,000 to $200,000 in the JV. Subsequent investments will be based on JV performance and mutual agreements between INVO Bioscience and Medesole. Medesole specializes in the distribution and marketing of medical technologies in India and the Middle East and is also present in the Commonwealth of Independent States with a mission to serve the healthcare industry with better technology for better health. By focusing on delivering proven technologies and products, Medesole ensures that they associate with only the best brands in the industry. In the infertility segment, Medesole works with customers on equipment planning for IVF centers and is a distributor of infertility products to medical institutions. While this JV represents the first IVF clinic for Medesole, the Company has extensive clinic management experience and has been running clinics across the Middle East. These clinics are focused on supporting the specific healthcare needs of the populations. In Qatar, Medesole's clinic is a recognized world-class healthcare institution. According to the Indian Society of Assisted Reproduction, between 10% and 14% of Indians struggle with their fertility. In 2015, 27.5 million couples in India seeking children experienced difficulty conceiving. In urban areas, one out of six couples are impacted. According to market research, the India IVF market is expected to reach $1.45 billion by 2026, a 14.7% increase from 2019. This double-digit growth of infertility in India has made it a personal, as well as public health issue. Social stigma apart, infertility leads to tremendous financial and emotional stress for couples with cost being a limiting factor for many couples who want to opt for this procedure. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, as well as parts of Africa and Eurasia for the INVOcell device. India marks the largest populated country for which INVOcell is available. The Company believes the worldwide fertility treatment market to be severely underserved with only 1% to 2% of the estimated 150 million infertile couples being treated. About the INVOcell Solution: The INVOcell system is a novel fertility treatment that uses a woman's own body as a natural incubator for the incubation of eggs and sperm during fertilization and early embryo development. The company believe this process is cost-effective and has shown comparable pregnancy rates to IVF and in their opinion has the ability to significantly increase patient access. It further believe the INVOcell system can eliminate the need for costly infrastructure and overhead associated with IVF, one of the primary hindering factors to fertility treatment in the continent. Their unique in vivo fertilization process also has the potential to serve as a powerful motivator for many patients with religious and/or cultural concerns.